Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04945772 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
A Phase 2 study of Retinitis Pigmentosa and Eye Diseases, sponsored by Nanoscope Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT04945772 is a Phase 2 study of Retinitis Pigmentosa and Eye Diseases that has completed, run by Nanoscope Therapeutics. The registered enrollment target is 27 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04945772, a Phase 2 study of Retinitis Pigmentosa and Eye Diseases, has completed, sponsored by Nanoscope Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
Conditions Studied
Interventions
- BIOLOGICAL Gene Therapy Product-MCO-010
- PROCEDURE Sham Injection
Study Locations (6)
Texas
- Nanoscope Clinical Site - Houston
- Nanoscope Clinical Site - McAllen
California
- Nanoscope Clinical Site - Beverly Hills
Florida
- Nanoscope Clinical Site - Pensacola
North Dakota
- Nanoscope Clinical Site - Fargo
Other
- Nanoscope Clinical Site - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04945772
The ClinicalTrials.gov registry entry for NCT04945772 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (90% lower). The listed sponsor is Nanoscope Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which Gene Therapy Product-MCO-010 is the first listed.
NCT04945772 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04945772 about?
NCT04945772 is a clinical study titled "Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]". The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
What is the current status of trial NCT04945772?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2021-07-13. Estimated completion is 2024-01-18.
What conditions does trial NCT04945772 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Eye Diseases, Retinal Degeneration, Eye Diseases, Hereditary, Retinal Dystrophies.
What interventions are being tested in trial NCT04945772?
The interventions under investigation include: Gene Therapy Product-MCO-010 (BIOLOGICAL), Sham Injection (PROCEDURE).
Who is sponsoring clinical trial NCT04945772?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04945772 being conducted?
This trial has 6 study locations across California, Florida, North Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
COMPLETED · Phase 2
-
Trial of Oral Valproic Acid for Retinitis Pigmentosa
COMPLETED · Phase 2
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.